Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial

Background: Most patients with type 1 diabetes do not achieve their glycemic targets. We aimed to assess the efficacy of glucose-responsive insulin and glucagon closed-loop delivery for controlling glucose levels in adults with type 1 diabetes. Methods: We conducted a randomized crossover trial involving 15 adults with type 1 diabetes, comparing standard insulin-pump therapy with dual-hormone, closed-loop delivery. Patients were admitted twice to a clinical research facility and received, in random order, both treatments. Each 15-hour visit (from 1600 to 0700) included an evening exercise session, followed by a medium-sized meal, a bedtime snack and an overnight stay. During visits that involved closed-loop delivery, basal insulin and glucagon miniboluses were delivered according to recommendations based on glucose sensor readings and a predictive dosing algorithm at 10-minute intervals. During visits involving standard insulin-pump therapy (control visits), patients used conventional treatment. Results: Dual-hormone closed-loop delivery increased the percentage of time for which patients’ plasma glucose levels were in the target range (median 70.7% [interquartile range (IQR) 46.1%–88.4%] for closed-loop delivery v. 57.3% [IQR 25.2%–71.8%] for control, p = 0.003) and decreased the percentage of time for which plasma glucose levels were in the low range (bottom of target range [< 4.0 mmol/L], 0.0% [IQR 0.0%–3.0%] for closed-loop delivery v. 10.2% [IQR 0.0%–13.0%] for control, p = 0.01; hypoglycemia threshold [< 3.3 mmol/L], 0.0% [IQR 0.0%–0.0%] for closed-loop delivery v. 2.8% [IQR 0.0%–5.9%] for control, p = 0.006). Eight participants (53%) had at least 1 hypoglycemic event (plasma glucose < 3.0 mmol/L) during standard treatment, compared with just 1 participant (7%) during closed-loop treatment (p = 0.02). Interpretation: Dual-hormone, closed-loop delivery guided by advanced algorithms improved short-term glucose control and reduced the risk of hypoglycemia in a group of 15 adults with type 1 diabetes. Trial registration: ClinicalTrials.gov, no. NCT01297946.

• Publication year

  2013

• Venue

  Canadian Medical Association Journal

• Publication date

  2013-03-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1503/cmaj.121265PMID 23359039PMCID PMC3589308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood Glucose Control in Type 1 Diabetes With a Bihormonal Bionic Endocrine Pancreas

  2012cited by this paper
• Fully Integrated Artificial Pancreas in Type 1 Diabetes

  2012cited by this paper
• Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies

  2011influential reference
• Closed-loop insulin delivery: from bench to clinical practice

  2011cited by this paper
• Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes

  2010cited by this paper
• Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results

  2010cited by this paper
• A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes

  2010cited by this paper
• Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring

  2010cited by this paper
• Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

  2010cited by this paper
• MD-Logic Artificial Pancreas System

  2010cited by this paper
• In Vitro and in Vivo Evaluation of Native Glucagon and Glucagon Analog (MAR-D28) during Aging: Lack of Cytotoxicity and Preservation of Hyperglycemic Effect

  2010cited by this paper
• Stabilized Glucagon Formulation for Bihormonal Pump Use

  2010cited by this paper
• MD-Logic Artificial Pancreas System: A Pilot Study in Adults with Type 1 Diabetes Mellitus Running Title: Closed-Loop System In Type 1 Diabetes

  2010cited by this paper
• Prolonged Nocturnal Hypoglycemia Is Common During 12 Months of Continuous Glucose Monitoring in Children and Adults With Type 1 Diabetes

  2010cited by this paper
• Response to Nocturnal Alarms Using a Real-Time Glucose Sensor

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control.

  2003cited by this paper
• Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

  2003cited by this paper
• Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*

  2002cited by this paper
• Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

  2000cited by this paper
• Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

  1998cited by this paper
• Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.

  1997cited by this paper
• The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• WEARABLE ARTIFICIAL ENDOCRINE PANCREAS WITH NEEDLE-TYPE GLUCOSE SENSOR

  1982cited by this paper
• Wearable artificial endocrine pancrease with needle-type glucose sensor.

  1982cited by this paper

• Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis

  2025cites this paper
• Automated Insulin Delivery and Glycemic Control in the Gulf Region: A Contemporary Systematic Review of Clinical Outcomes

  2025cites this paper
• Dual hormone predictive control for a fully automated intraperitoneal artificial pancreas: Preclinical evaluation in pigs

  2025cites this paper
• On effectiveness of AI-based misbehavior detection in medical IoT

  2025cites this paper
• A Glucose-Responsive Glucagon-Micelle for the Prevention of Hypoglycemia

  2024cites this paper
• Themes, Rates, and Risk of Adverse Events of the Artificial Pancreas in the United States Using MAUDE

  2024cites this paper
• Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?

  2023cites this paper
• Blood Glucose Regulation Models in Artificial Pancreas for Type-1 Diabetic Patients

  2023cites this paper
• Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies

  2023cites this paper
• A wearable, minimally-invasive, fully electrochemically-controlled feedback minisystem for diabetes management.

  2023cites this paper
• The efficacy of glucose‐responsive insulin and glucagon delivery on exercise‐induced hypoglycaemia among adults with type 1 diabetes mellitus: A meta‐analysis of randomized controlled trials

  2023cites this paper
• Efficacy of treatment of non-severe hypoglycemia in adults with type 1 diabetes using oral carbohydrates during automated insulin delivery with and without glucagon.

  2023cites this paper
• Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs.

  2022cites this paper
• Dual‐hormone artificial pancreas for glucose control in type 1 diabetes: A meta‐analysis

  2022cites this paper
• "Smart" Composite Microneedle Patch Stabilizes Glucagon and Prevents Nocturnal Hypoglycemia: Experimental Studies and Molecular Dynamics Simulation.

  2022cites this paper
• An event-triggered active disturbance rejection approach to dual-hormonal artificial pancreas control

  2022cites this paper
• Efficacy of insulin dosing algorithms for high‐fat high‐protein mixed meals to control postprandial glycemic excursions in people living with type 1 diabetes: A systematic review and meta‐analysis

  2022cites this paper
• Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence

  2021cites this paper
• A Light Activated Glucagon Trimer with Resistance to Fibrillation.

  2021cites this paper
• Adjunctive Therapies to Optimize Closed-loop Glucose Control

  2021cites this paper
• Distal Pancreatectomy, Pancreatoduodenectomy and Total Pancreatectomy for Pancreatic Neuroendocrine Tumors – Same Organ, Different Outcomes

  2021cites this paper
• Insulin Delivery Using Dynamic Covalent Boronic Acid/Ester‐Controlled Release

  2021cites this paper
• Glucagon delivery - An overview of current and future devices.

  2021cites this paper
• Neue Entwicklungen bei Diabetes mellitus Typ 1

  2021cites this paper
• Feedback and Control Systems

  2021cites this paper
• Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.

  2021cites this paper
• Development platform for artificial pancreas algorithms

  2020cites this paper
• Role of Glucagon in Automated Insulin Delivery.

  2020cites this paper
• STOCHASTIC SEASONAL MODELS FOR GLUCOSE PREDICTION IN TYPE 1 DIABETES

  2020cites this paper
• A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial

  2020cites this paper
• Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.

  2020cites this paper
• Chattering-free hybrid adaptive neuro-fuzzy inference system-particle swarm optimisation data fusion-based BG-level control.

  2020cites this paper
• A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies

  2020cites this paper
• Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial

  2020cites this paper
• Design of dual hormone blood glucose therapy and comparison with single hormone using MPC algorithm.

  2020cites this paper
• Solution of singularly perturbed differential difference equations and convection delayed dominated diffusion equations using Haar wavelet

  2020cites this paper
• The dawn of automated insulin delivery: from promise to product

  2020cites this paper
• In silico evaluation of a Parallel Control-based Coordinated Dual-Hormone Artificial Pancreas with Insulin on Board Limitation

  2019influential citation
• Insulin Pumps and Artificial Pancreas

  2019cites this paper
• Capabilities of Next-Generation Patch Pump: Improved Precision, Instant Occlusion Detection, and Dual-Hormone Therapy

  2019cites this paper
• Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.

  2019cites this paper
• Artificial Pancreas Systems and Physical Activity in Patients with Type 1 Diabetes: Challenges, Adopted Approaches, and Future Perspectives

  2019cites this paper
• Pharmacodynamic Evaluation: Diabetic Methodologies

  2019cites this paper
• Closed‐loop blood glucose control for type 1 diabetes

  2019cites this paper
• Chattering-free Higher Order Sliding Mode and Unscented Kalman Filter for Blood Glucose Level Control

  2019cites this paper
• Postprandial metabolic effects of fructose and glucose in type 1 diabetes patients: a pilot randomized crossover clinical trial

  2019cites this paper
• Sensor-based detection and estimation of meal carbohydrates for people with diabetes

  2019cites this paper
• Coordinated dual-hormone artificial pancreas with parallel control structure

  2019cites this paper
• Strategies to mitigate hypoglycaemia in the artificial pancreas

  2019cites this paper
• Improving Glucose Prediction Accuracy in Physically Active Adolescents With Type 1 Diabetes

  2019cites this paper
• Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines

  2019cites this paper
• Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue

  2018cites this paper
• Glycaemic control in pregnancies complicated by type 1 diabetes

  2018cites this paper
• Optimisation du contrôle glycémique des patients atteints de diabète de type 1 : traitement efficace des hypoglycémies, calcul des glucides et pancréas artificiel

  2018cites this paper
• Impact of erroneous meal insulin bolus with dual-hormone artificial pancreas using a simplified bolus strategy - A randomized controlled trial

  2018cites this paper
• The challenges of achieving postprandial glucose control using closed‐loop systems in patients with type 1 diabetes

  2018cites this paper
• Model-Fusion-Based Online Glucose Concentration Predictions in People with Type 1 Diabetes.

  2018cites this paper
• Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?

  2018cites this paper
• Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems

  2018cites this paper
• Clinical implications of persistent beta cell function in long duration type 1 diabetes

  2018cites this paper
• Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial

  2018cites this paper
• Impact of macronutrient content of meals on postprandial glucose control in the context of closed‐loop insulin delivery: A randomized cross‐over study

  2018cites this paper
• Efficacy and safety of the artificial pancreas in the paediatric population with type 1 diabetes

  2018cites this paper
• ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies

  2018cites this paper
• Multivariable Artificial Pancreas for Various Exercise Types and Intensities

  2018cites this paper
• Meal Detection for Type 1 Diabetes Using Moving Horizon Estimation

  2018cites this paper
• Considerations for Construct and Affinity Design Goals

  2018cites this paper
• Dual treatment with a fixed ratio of glucagon and insulin increases the therapeutic window of insulin in diabetic rats

  2018cites this paper
• Analyzing the Potential of Advanced Insulin Dosing Strategies in Patients With Type 2 Diabetes: Results From a Hybrid In Silico Study

  2018cites this paper
• Differential Temperature Evolution for Insulin Delivery Monitoring in Type 1 Diabetic Patients before and after Kidney-Pancreas Transplantation

  2017cites this paper
• Modeling Pharmacokinetics and Pharmacodynamics of Glucagon for Simulation of the Glucoregulatory System in Patients with Type 1 Diabetes.

  2017cites this paper
• Do youth with type 1 diabetes exercise safely? A focus on patient practices and glycemic outcomes

  2017cites this paper
• Has Faetal Whole Faetal Pancreas Grafting Some Perspectives among the Surgical Methods of Diabetes Mellitus Treatment?

  2017cites this paper
• Automated Insulin Delivery—The Light at the End of the Tunnel

  2017cites this paper
• O Glucagon na Diabetes Tipo 1 e o seu Potencial Terapêutico

  2017cites this paper
• Modeling Glucagon Action in Patients With Type 1 Diabetes

  2017cites this paper
• Automated blood glucose control in type 1 diabetes: A review of progress and challenges.

  2017cites this paper
• Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label, randomised, crossover, controlled trial

  2017cites this paper
• Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes

  2017cites this paper
• Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.

  2017cites this paper
• Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use

  2017cites this paper
• Practices, perceptions and expectations for carbohydrate counting in patients with type 1 diabetes - Results from an online survey.

  2017cites this paper
• Islet Transplantation Provides Superior Glycemic Control With Less Hypoglycemia Compared With Continuous Subcutaneous Insulin Infusion or Multiple Daily Insulin Injections

  2017cites this paper
• Closed-Loop Control of Postprandial Glycemia Using an Insulin-on-Board Limitation Through Continuous Action on Glucose Target

  2017cites this paper
• Impact of Sensing and Actuation Characteristics on Artificial Pancreas Design

  2016cites this paper
• The Artificial Pancreas: How Closed-Loop Control Is Revolutionizing Diabetes

  2016influential citation
• Closed-loop glycaemic control using an implantable artificial pancreas in diabetic domestic pig (Sus scrofa domesticus).

  2016cites this paper
• Hypoglycemia Detection and Carbohydrate Suggestion in an Artificial Pancreas

  2016cites this paper
• Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial

  2016cites this paper
• Novel Methods of Insulin Replacement: The Artificial Pancreas and Encapsulated Islets.

  2016cites this paper
• A Simplified Semiquantitative Meal Bolus Strategy Combined with Single- and Dual-Hormone Closed-Loop Delivery in Patients with Type 1 Diabetes: A Pilot Study

  2016cites this paper
• Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide

  2016cites this paper
• Reducing Glucose Variability Due to Meals and Postprandial Exercise in T1DM Using Switched LPV Control

  2016cites this paper
• Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.

  2016cites this paper
• Association of aerobic fitness level with exercise‐induced hypoglycaemia in Type 1 diabetes

  2016cites this paper
• Wie nah sind wir am artifiziellen Pankreas?

  2016cites this paper
• Utility of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes.

  2016cites this paper
• Future Drug Treatments for Type 1 Diabetes

  2016cites this paper
• Integrated system for an automated insulin therapy for type 1 diabetes : real time evaluation of the effect of physical exercise and adjustment of the insulin dosage.

  2016cites this paper
• PK/PD modelling of glucose-insulin-glucagon dynamics in healthy dogs after a subcutaneous bolus administration of native glucagon or a novel glucagon analogue

  2016cites this paper